Literature DB >> 27567105

Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis.

Masahiro Satake1, Masako Iwanaga2, Yasuko Sagara3, Toshiki Watanabe4, Kazu Okuma5, Isao Hamaguchi5.   

Abstract

BACKGROUND: Human T-lymphotropic virus 1 (HTLV-1) infection has an especially high prevalence in Japan. Transmission has been confirmed in infancy through breastfeeding; however, little is known about the epidemiological aspects of new HTLV-1 infections later in life. We aimed to estimate the nationwide annual number of new HTLV-1 infections among adolescents and adults in Japan.
METHODS: In this retrospective cohort analysis, we assessed new HTLV-1 infections of repeat blood donors aged 16-69 years between Jan 1, 2005, and Dec 31, 2006, in the Japanese Red Cross Blood Centres database. We used results of antibody tests done in repeat blood samples collected until Dec 31, 2011, to assess the number who seroconverted to HTLV-1. We calculated the incidence density by dividing the number of seroconverters by the number of person-years of follow-up, and then extrapolated densities to regional populations to estimate the annual number of new HTLV-1 infections.
FINDINGS: We included 3 375 821 HTLV-1-seronegative blood donors (2 100 915 men and 1 274 906 women). Within a median follow-up of 4·5 years (IQR 2·3-5·8), 532 people (204 men and 328 women) had seroconverted. The incidence density was significantly higher in women (6·88 per 100 000 person-years; 95% CI 6·17-7·66) than in men (2·29 per 100 000 person-years; 95% CI 1·99-2·62; p<0·0001). The estimated annual number of new HTLV-1 infections was 4190 (95% CI 4064-4318) with 975 (914-1038) infections in men and 3215 (3104-3328) in women.
INTERPRETATION: New HTLV-1 infections in adolescents and adults are an important public health concern in Japan and preventive strategies are needed to reduce new transmission. FUNDING: Ministry of Health, Labour, and Welfare of Japan; Japan Agency for Medical Research and Development.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27567105     DOI: 10.1016/S1473-3099(16)30252-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  32 in total

1.  Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area.

Authors:  Daisuke Nakamura; Makoto Yoshimitsu; Tomohisa Tabuchi; Naosuke Arima; Maiko Hayashida; Hirosaka Inoue; Kakushi Matsushita; Tadashi Matsumoto; Naomichi Arima; Kenji Ishitsuka
Journal:  Int J Hematol       Date:  2019-11-12       Impact factor: 2.490

Review 2.  Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells.

Authors:  Toshiki Watanabe
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

3.  Novel Genetic Constructs for Production of Recombinant HTLV-1/2 Antigens and Evaluation of Their Reactivity to Plasma Samples from HTLV-1-Infected Patients.

Authors:  Ueriton Dias de Oliveira; Fred Luciano Neves Santos; Bernardo Galvão-Castro; Marco Aurelio Krieger; Nilson Ivo Tonin Zanchin
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

4.  In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection.

Authors:  Ria Mulherkar; Aykan Karabudak; Rashida Ginwala; Xiaofang Huang; Aileen Rowan; Ramila Philip; Edward L Murphy; Danielle Clements; Lishomwa C Ndhlovu; Zafar K Khan; Pooja Jain
Journal:  Vaccine       Date:  2018-07-10       Impact factor: 3.641

Review 5.  HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.

Authors:  Nicolas Futsch; Renaud Mahieux; Hélène Dutartre
Journal:  Viruses       Date:  2017-12-21       Impact factor: 5.048

6.  Seroprevalence and geographical distribution of human T-lymphotropic virus type 1 among volunteer blood donors in endemic areas of Iran.

Authors:  Gharib Karimi; Maryam Zadsar; Ali Akbar Pourfathollah
Journal:  Virol J       Date:  2017-01-30       Impact factor: 4.099

7.  Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey.

Authors:  Kisato Nosaka; Masako Iwanaga; Yoshitaka Imaizumi; Kenji Ishitsuka; Kenichi Ishizawa; Yoji Ishida; Masahiro Amano; Takashi Ishida; Naokuni Uike; Atae Utsunomiya; Koichi Ohshima; Kazuhiro Kawai; Junji Tanaka; Yoshiki Tokura; Kensei Tobinai; Toshiki Watanabe; Kaoru Uchimaru; Kunihiro Tsukasaki
Journal:  Cancer Sci       Date:  2017-10-08       Impact factor: 6.716

8.  Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.

Authors:  Kenta Tezuka; Kazu Okuma; Madoka Kuramitsu; Sahoko Matsuoka; Reiko Tanaka; Yuetsu Tanaka; Isao Hamaguchi
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 9.  Epidemiology of HTLV-1 Infection and ATL in Japan: An Update.

Authors:  Masako Iwanaga
Journal:  Front Microbiol       Date:  2020-05-29       Impact factor: 5.640

10.  Fine-scale geographic clustering pattern of human T-cell leukemia virus type 1 infection among blood donors in Kyushu-Okinawa, Japan.

Authors:  Yasuko Sagara; Masako Iwanaga; Maiko Morita; Yasuhiro Sagara; Hitomi Nakamura; Hideaki Hirayama; Kazuo Irita
Journal:  J Med Virol       Date:  2018-07-10       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.